explore -WSS

explore

author：leisure time 2025-09-29 00:38:56 - browse：817

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Key Senate committee drafts bipartisan bill to stem drug shortages

WSS

Cue Health's Covid

FDA sets aggressive timeline for overhauling inspection procedures

H5N1 bird flu virus started spreading in cows in Texas in December

Health care needs a new profession: neuroimaging counseling

Bird flu in milk supply is likely coming from asymptomatic cows

Bird flu in milk supply is likely coming from asymptomatic cows

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Jerome Adams on the need for new antivirals for Covid

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Cancer drug shortages should be causing more outrage

Medical bills so high, Medicare adding extra digits to claim forms

Apple is now the first public company to be valued at $3 trillion

Why does health care cost so much? A reading guide

New air purifier tech could be key to improving indoor air quality

FDA endorses new sterilization method for medical devices

George Santos makes 1st court appearance after pleading not guilty to 13 counts

After traumatic brain injury, life support decisions can use more time

knowledge

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Cardiologists urge adding sexual orientation, gender identity to health records

Cardiologists urge adding sexual orientation, gender identity to health records

Flu vaccine reformulation won't be easy, manufacturers warn

To bolster infectious disease surveillance, genomics powerhouses team up

Prior authorization reform is both possible and imperative

focus

Wikipedia

entertainment

hotspot